Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUPH Aurinia Pharmaceuticals	$8.39 +10.5%	$8.04	$5.20 ▼ $10.67	$1.03B	1.16	1.38 million shs	2.58 million shs
CMPX Compass Therapeutics	$2.74 +3.4%	$2.27	$0.87 ▼ $4.08	$366.45M	1.48	968,153 shs	598,393 shs
MLYS Mineralys Therapeutics	$14.37 +3.0%	$14.95	$8.24 ▼ $18.38	$909.20M	-0.3	551,548 shs	596,239 shs
RCUS Arcus Biosciences	$9.31 +9.5%	$8.85	$6.50 ▼ $18.98	$900.02M	0.8	881,434 shs	818,492 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUPH Aurinia Pharmaceuticals	+10.54%	+12.02%	+3.07%	+14.31%	+51.99%
CMPX Compass Therapeutics	+3.40%	+4.58%	+6.61%	+66.06%	+216.40%
MLYS Mineralys Therapeutics	+3.01%	+0.49%	-11.24%	+17.88%	+11.48%
RCUS Arcus Biosciences	+9.14%	+8.38%	-5.58%	+24.38%	-33.92%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AUPH Aurinia Pharmaceuticals	2.7339 of 5 stars	3.5	1.0	2.5	0.8	1.9
CMPX Compass Therapeutics	2.4536 of 5 stars	3.6	2.0	0.0	5.0	0.0
MLYS Mineralys Therapeutics	2.1542 of 5 stars	3.4	1.0	1.4	4.2	0.0
RCUS Arcus Biosciences	2.5618 of 5 stars	4.4	3.0	0.0	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AUPH Aurinia Pharmaceuticals	3.00	Buy	$11.50	37.07% Upside
CMPX Compass Therapeutics	3.10	Buy	$12.67	362.29% Upside
MLYS Mineralys Therapeutics	2.75	Moderate Buy	$32.25	124.43% Upside
RCUS Arcus Biosciences	2.89	Moderate Buy	$21.29	128.63% Upside

Current Analyst Ratings Breakdown

Latest CMPX, AUPH, MLYS, and RCUS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/1/2025	CMPX Compass Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform	$9.00
6/17/2025	MLYS Mineralys Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00
6/10/2025	MLYS Mineralys Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold	$15.00
5/14/2025	MLYS Mineralys Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$48.00
5/13/2025	MLYS Mineralys Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00 ➝ $42.00
5/9/2025	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $10.00
5/9/2025	RCUS Arcus Biosciences	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$24.00 ➝ $22.00
5/8/2025	RCUS Arcus Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$15.00 ➝ $13.00
5/7/2025	RCUS Arcus Biosciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$33.00
5/7/2025	RCUS Arcus Biosciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$29.00 ➝ $26.00
4/28/2025	CMPX Compass Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00

(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AUPH Aurinia Pharmaceuticals	$235.13M	4.82	$0.34 per share	24.61	$2.68 per share	3.13
CMPX Compass Therapeutics	$850K	445.75	N/A	N/A	$0.91 per share	3.01
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	$3.84 per share	N/A
RCUS Arcus Biosciences	$141M	6.99	N/A	N/A	$5.30 per share	1.76

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AUPH Aurinia Pharmaceuticals	$5.75M	$0.28	29.96	14.98	N/A	16.11%	14.27%	9.93%	7/30/2025 (Estimated)
CMPX Compass Therapeutics	-$49.38M	-$0.41	N/A	N/A	N/A	N/A	-42.47%	-38.31%	8/11/2025 (Estimated)
MLYS Mineralys Therapeutics	-$177.81M	-$3.73	N/A	N/A	N/A	N/A	-71.15%	-65.71%	8/12/2025 (Estimated)
RCUS Arcus Biosciences	-$283M	-$4.19	N/A	N/A	N/A	-258.94%	-70.58%	-32.97%	8/4/2025 (Estimated)

Latest CMPX, AUPH, MLYS, and RCUS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	AUPH Aurinia Pharmaceuticals	$0.18	N/A	N/A	N/A	$64.27 million	N/A
5/12/2025	Q1 2025	AUPH Aurinia Pharmaceuticals	$0.08	$0.16	+$0.08	$0.16	$61.06 million	$62.47 million
5/12/2025	Q1 2025	MLYS Mineralys Therapeutics	-$1.02	-$0.79	+$0.23	-$0.79	N/A	N/A
5/8/2025	Q1 2025	CMPX Compass Therapeutics	-$0.12	-$0.12	N/A	-$0.12	N/A	N/A
5/6/2025	Q1 2025	RCUS Arcus Biosciences	-$1.02	-$1.14	-$0.12	-$1.14	$38.61 million	$28.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AUPH Aurinia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	N/A
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	N/A
RCUS Arcus Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AUPH Aurinia Pharmaceuticals	0.16	5.93	5.26
CMPX Compass Therapeutics	N/A	8.33	8.33
MLYS Mineralys Therapeutics	N/A	26.48	26.48
RCUS Arcus Biosciences	0.09	5.37	5.37

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AUPH Aurinia Pharmaceuticals	36.83%
CMPX Compass Therapeutics	68.43%
MLYS Mineralys Therapeutics	84.46%
RCUS Arcus Biosciences	92.89%

Insider Ownership

Company	Insider Ownership
AUPH Aurinia Pharmaceuticals	12.20%
CMPX Compass Therapeutics	29.80%
MLYS Mineralys Therapeutics	25.56%
RCUS Arcus Biosciences	9.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AUPH Aurinia Pharmaceuticals	300	135.10 million	118.62 million	Optionable
CMPX Compass Therapeutics	20	138.28 million	97.08 million	Not Optionable
MLYS Mineralys Therapeutics	28	65.18 million	48.52 million	Optionable
RCUS Arcus Biosciences	500	105.89 million	95.72 million	Optionable

CMPX, AUPH, MLYS, and RCUS Headlines

Recent News About These Companies

Arcus Biosciences (NYSE:RCUS) Stock Price Up 8.1% - Should You Buy?

July 9 at 6:28 PM | marketbeat.com

Arcus Biosciences Announces New Employment Inducement Grants

July 9 at 4:35 PM | businesswire.com

Arcus Biosciences (NYSE:RCUS) Trading Down 2.9% - Here's What Happened

July 3, 2025 | marketbeat.com

Arcus Biosciences Presents First Postive Data for Oral Metastatic Kidney Cancer Treatment

July 1, 2025 | msn.com

Arcus Biosciences (NYSE:RCUS) Trading Down 6.3% - Here's What Happened

June 27, 2025 | marketbeat.com

Incyte, FDA, Sun Pharma and more—Chutes & Ladders

June 27, 2025 | fiercebiotech.comF

Arcus Biosciences Announces New Employment Inducement Grants - Business Wire

June 26, 2025 | businesswire.com

Precision Bio's DMD Therapy Gets Rare Pediatric Status, But Stock Slides; Retail Crowd Sees ‘Good Risk-Reward’

June 26, 2025 | msn.com

Precision BioSciences Shares Surge Following FDA Rare Pediatric Disease Designation

June 25, 2025 | msn.com

Precision BioSciences gets FDA rare disease status for DMD treatment, stock jumps 10%

June 25, 2025 | msn.com

Arcus Biosciences, Inc. (RCUS) Cash Flow - Yahoo Finance

June 24, 2025 | finance.yahoo.com

RCUS Arcus Biosciences, Inc. - Seeking Alpha

June 24, 2025 | seekingalpha.com

Arcus Biosciences Announces New Employment Inducement Grants

June 24, 2025 | businesswire.com

Arcus Biosciences, Inc. (NYSE:RCUS) Given Consensus Rating of "Moderate Buy" by Analysts

June 23, 2025 | marketbeat.com

The trouble with TIGITs: How 'overenthusiasm' led to Big Pharma's risky $6B gamble

June 13, 2025 | fiercebiotech.comF

Arcus Biosciences (NYSE:RCUS) Shares Down 3.8% - What's Next?

June 11, 2025 | marketbeat.com

Stock Traders Purchase Large Volume of Call Options on Arcus Biosciences (NYSE:RCUS)

June 11, 2025 | marketbeat.com

Arcus Biosciences Announces New Employment Inducement Grants

June 10, 2025 | businesswire.com

Research Analysts Offer Predictions for RCUS FY2026 Earnings

June 10, 2025 | marketbeat.com

H.C. Wainwright maintains Buy rating for Arcus Biosciences stock

June 4, 2025 | investing.com

Arcus Kidney Cancer Drug Casdatifan Advances to Challenge Merck’s Welireg

June 2, 2025 | biospace.comB

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPX, AUPH, MLYS, and RCUS Company Descriptions

Aurinia Pharmaceuticals NASDAQ:AUPH

$8.39 +0.80 (+10.54%)

Closing price 07/9/2025 04:00 PM Eastern

Extended Trading

$8.32 -0.07 (-0.77%)

As of 08:35 AM Eastern

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Compass Therapeutics NASDAQ:CMPX

$2.74 +0.09 (+3.40%)

Closing price 07/9/2025 04:00 PM Eastern

Extended Trading

$2.80 +0.05 (+2.01%)

As of 08:30 AM Eastern

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Mineralys Therapeutics NASDAQ:MLYS

$14.37 +0.42 (+3.01%)

Closing price 07/9/2025 04:00 PM Eastern

Extended Trading

$14.14 -0.23 (-1.60%)

As of 08:30 AM Eastern

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Arcus Biosciences NYSE:RCUS

$9.31 +0.81 (+9.53%)

Closing price 07/9/2025 03:56 PM Eastern

Extended Trading

$9.57 +0.26 (+2.78%)

As of 08:36 AM Eastern

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time